Figure 5.

Percentages of Gag-specific interferon (IFN) γ, interleukin (IL) 2, tumor necrosis factor (TNF) α, or CD107a CD8⁺ and CD4⁺ T cell responses in gut-associated lymphoid tissue (GALT). RGV, raltegravir (red); PBO, placebo (blue). Thin lines represent raw data for each subject; thick lines, estimated mean values over time from generalized estimating equations for each group. Raltegravir intensification had no effect on Gag-specific IFN-γ, IL-2, TNF-α, or CD107a CD8⁺ (A) (P = .91) or CD4⁺ (B) (P = .30) T cell responses in GALT.